MSC-1 (Northern Biologics)

N/A

Report date: 2025/06/20 20:01:04

Base Information

Drug NameMSC-1 (Northern Biologics)
Drug Alias Nameanti-LIF mAb (Northern Biologics/Bristol-Myers Squibb)MSC-1 (Mosaic Biomedicals)MSC-1 (Northern Biologics/Celgene)anti-LIF mAb (Northern Biologics)anti-leukemia inhibitory factor mAb (Northern Biologics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeukemia inhibitory factor receptor antagonistsT lymphocytes stimulantsAminopeptidase N inhibitors +[4] 
TargetsAminopeptidase NLeukemia inhibitory factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesEurope +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMosaic Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesNorthern Biologics IncBristol-Myers Squibb Company
Inactive CompaniesMosaic BiosciencesCelgene Corp
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A